Implantable Cardioverter-Defibrillators: Clinical Aspects

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 980-994

  Swerdlow, Charles D ^a,b   Shivkumar, Kalyanam ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904142482     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50110-X     Document Type: Chapter

References (55)

1. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000, 21:2071-2078.
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
3. Ruskin JN, Camm AJ, Zipes DP, et al. Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol 2002, 13:38-43.
4. Gregoratos G, Abrams J, Epstein A, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee on Pacemaker Implantation), 2002: Available at. http://www.acc.org/clinical/guidelines/pacemaker/pacemaker.pdf.
5. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias: The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997, 337:1576-1583.
6. Schoels W, Swerdlow CD, Jung W, et al. Worldwide clinical experience with a new dual-chamber implantable cardioverter defibrillator system. J Cardiovasc Electrophysiol 2001, 12:521-528.
7. Swerdlow CD Implantation of cardioverter defibrillators without induction of ventricular fibrillation. Circulation 2001, 103:2159-2164.
8. Natale A, Sra J, Axtell K, et al. Undetected ventricular fibrillation in transvenous implantable cardioverter-defibrillators: Prospective comparison of different lead system-device combinations. Circulation 1996, 93:91-98.
9. Glikson M, Trusty JM, Grice SK, et al. A stepwise testing protocol for modern implantable cardioverter-defibrillator systems to prevent pacemaker-implantable cardioverter-defibrillator interactions. Am J Cardiol 1999, 83:360-366.
10. Shivkumar K, Feliciano Z, Boyle NG, Wiener I Intradevice interaction in a dual chamber implantable cardioverter defibrillator preventing ventricular tachyarrhythmia detection. J Cardiovasc Electrophysiol 2000, 11:1285-1288.
11. DeGroot PJ, Church TR, Mehra R, et al. Derivation of a defibrillator implant criterion based on probability of successful defibrillation. Pacing Clin Electrophysiol 1997, 20:1924-1935.
12. Li H, Malkin RA An approximate bayesian up-down method for estimating a percentage point on a dose-response curve. J Appl Stat 2000, 27:579-587.
13. Gold MR, Higgins S, Klein R, et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: Primary results from the Low Energy Safety Study (LESS). Circulation 2002, 105:2043-2048.
14. Swerdlow C, Martin D, Kass R, et al. The zone of vulnerability to T-wave shocks in humans. J Cardiovasc Electrophysiol 1997, 8:145-154.
15. Swerdlow C, Peter C, Hwang C, et al. Programming of implantable defibrillators based on the upper limit of vulnerability rather than the defibrillation threshold. Circulation 1997, 95:1497-1504.
16. Swerdlow C, Ahern T, Kass R, et al. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter defibrillators. J Am Coll Cardiol 1996, 27:1112-1117.
17. Swerdlow C, Davie S, Ahern T, Chen PS Comparative reproducibility of defibrillation threshold and upper limit of vulnerability. Pacing Clin Electrophysiol 1996, 19:2103-2111.
18. Marchlinski FE, Flores B, Miller JM, et al. Relation of the intraoperative defibrillation threshold to successful postoperative defibrillation with an automatic implantable cardioverter defibrillator. Am J Cardiol 1988, 62:393-398.
19. Strickberger SA, Man KC, Souza J, et al. A prospective evaluation of two defibrillation safety margin techniques in patients with low defibrillation energy requirements. J Cardiovasc Electrophysiol 1998, 9:41-46.
20. Malkin RA, Herre JM, McGowen L, et al. A four-shock Bayesian up-down estimator of the 80% effective defibrillation dose. J Cardiovasc Electrophysiol 1999, 10:973-980.
21. Tokano T, Pelosi F, Flemming M, et al. Long-term evaluation of the ventricular defibrillation energy requirement. J Cardiovasc Electrophysiol 1998, 9:916-920.
22. Pelosi F, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000, 11:736-740.
23. Hodgson DM, Olsovsky MR, Shorofsky SR, et al. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol 2002, 25:408-413.
24. Merkely B, Lubinski A, Kiss O, et al. Shortening the second phase duration of biphasic shocks: Effects of class III antiarrhythmic drugs on defibrillation efficacy in humans. J Cardiovasc Electrophysiol 2001, 12:824-827.
25. Dorian P Amiodarone and defibrillation thresholds: A clinical conundrum. J Cardiovasc Electrophysiol 2000, 11:741-743.
26. Gold MR, Olsovsky MR, DeGroot PJ, et al. Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol 2000, 11:25-29.
27. Gradaus R, Block M, Seidl K, et al. Defibrillation efficacy comparing a subcutaneous array electrode versus an "active can" implantable cardioverter defibrillator and a subcutaneous array electrode in addition to an "active can" implantable cardioverter defibrillator: Results from active can versus array trials I and II. J Cardiovasc Electrophysiol 2001, 12:921-927.
28. Mouchawar G, Kroll M, Val-Mejias JE, et al. ICD waveform optimization: A randomized, prospective, pair-sampled multicenter study. Pacing Clin Electrophysiol 2000, 23:1992-1995.
29. Shorofsky SR, Gold MR Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol 1996, 78:313-316.
30. Schaumann A, Von Zur Muhlen F, Herse B, et al. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: A prospective study including 200 patients. Circulation 1998, 97:66-74.
31. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001, 104:796-801.
32. Bansch D, Castrucci M, Bocker D, et al. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: Incidence, prediction and significance. J Am Coll Cardiol 2000, 36:557-565.
33. Swerdlow CD Supraventricular tachycardia-ventricular tachycardia discrimination algorithms in implantable cardioverter defibrillators: State-of-the-art review. J Cardiovasc Electrophysiol 2001, 12:606-612.
34. Pinski SL, Fahy GJ The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995, 92:1651-1664.
35. Dorian P, Newman D, Thibault B, et al. A randomized clinical trial of a standardized protocol for the prevention of inappropriate therapy using a dual chamber implantable cardioverter defibrillator [abstract]. Circulation 1999, 1:I-786.
36. Wilkoff BL, Kuhlkamp V, Volosin K, et al. Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection: Results and technical considerations. Circulation 2001, 103:381-386.
37. Lloyd M, Hayes D, Friedman P Troubleshooting. Cardiac Pacing and Defibrillation: A Clinical Approach 2000, 347-452. Futura, Armonk, NY. D. Hayes, M. Lloyd, P. Friedman (Eds.).
38. Gunderson B, Patel A, Bounds C Automatic identification of implantable cardioverter-defibrillator lead problems using intracardiac electrograms. Comput Cardiol 2002, 29:121-124.
39. Schreieck J, Zrenner B, Kolb C, et al. Inappropriate shock delivery due to ventricular double detection with a biventricular pacing implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2001, 24:1154-1157.
40. Sweeney MO, Ellison KE, Shea JB, Newell JB Provoked and spontaneous high-frequency, low-amplitude, respirophasic noise transients in patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 2001, 12:402-410.
41. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999, 340:1855-1862.
42. Goldschlager N, Epstein A, Friedman P, et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: A practical guide to patient treatment. Arch Intern Med 2001, 161:649-655.
43. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002, 105:589-594.
44. Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: Implications for regulation and physician recommendations-A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996, 94:1147-1166.
45. Akiyama T, Powell JL, Mitchell LB, et al. Resumption of driving after life-threatening ventricular tachyarrhythmia. N Engl J Med 2001, 345:391-397.
46. Pinski SL, Trohman RG Interference in implanted cardiac devices, part II. Pacing Clin Electrophysiol 2002, 25:1496-1509.
47. Pinski SL, Trohman RG Interference in implanted cardiac devices, Part I. Pacing Clin Electrophysiol 2002, 25:1367-1381.
48. Best PJ, Hayes DL, Stanton MS The potential usage of dual chamber pacing in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1999, 22:79-85.
49. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002, 288:3115-3123. Dual Chamber and VVI Implantable Defibrillator Trial Investigators,.
50. Hügl B, Ziegenbalg K, Grosse A, et al. Are enhanced dual chamber detection algorithm superior to single chamber algorithm? Long term results of the multicenter ICD-Trial DETECT. Circulation 2002, 106:II-321.
51. The Companion Trial Investigators To be presented at ACC Meeting 2003. J Am Coll Cardiol 2003.
52. Kuhlkamp V Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J Am Coll Cardiol 2002, 39:790-797.
53. Butter C, Meisel E, Tebbenjohanns J, et al. Transvenous biventricular defibrillation halves energy requirements in patients. Circulation 2001, 104:2533-2538.
54. Zipes DP Implantable cardioverter-defibrillator: A Volkswagen or a Rolls Royce-how much will we pay to save a life?. Circulation 2001, 103:1372-1374.
55. Olson WH Tachyarrhythmia Sensing and Detection. Implantable Cardioverter Defibrillator 1994, 71-107. Futura, Armonk, NY. I. Singer (Ed.).